Prague 2012 Programme Hotels Exhibition Visa Information Satellite Meetings

Outcomes of flap-off Epi-LASIK without mytomycin for the correction of high myopia and myopic astigmatism- 3 years follow-up

Poster Details

First Author: K.DIAMANTOPOULOU GREECE

Co Author(s):    E. PATSOURA   B. NEUREITHER   S. GEORGARAS        

Abstract Details



Purpose:

To present the clinical outcomes of Epi-Lasik treatment in eyes with high myopia and myopic astigmatism (≥8,00 sph.eq.) 3 years post Laser.

Setting:

: OPHTHALMOS Research and Therapeutic Institute, Glyphada Athens, Greece Hygeia Ophthalmos Eye Center, Glyphada Athens, Greece

Methods:

This retrospective study comprised 46 eyes of 25 patients who underwent Epi-lasik for the correction of high myopia and myopic astigmatism (≥8,00 sph.eq.). Epi-Lasik procedure was performed with an automatic rotational Epi keratome (Bausch & Lomb XP Epi separator) and Technolas 100 (with ACE advanced eye tracker) Excimer Laser Bausch & Lomb. In 15 eyes the refractive target was myopia (range --0,5 to -1,5D) in order to achieve Monovision for presbyopia correction. The post operative pain, visual acuity, refraction and haze formation were investigated.

Results:

The follow up period was 36 months. The mean post-operative myopia was -8,05D, cylinder -1,33D and sph.eq. -8,71D. An integral epithelial sheet with a diameter of 8,5-9,5mm was made in all eyes and then removed. The mean epithelial healing time was 4,5 days under a bandage contact lens. At the end of 3 years follow up no eye lost any line of corrected distance visual aquity (CDVA). The mean post-operative myopia was (-0,36D) cylinder (-0,22D) and sp.eq.(-0,47D). at the end of the follow up. 5 eyes (10%) had persisting trace of haze (grade o,5) at the end of the follow up period and the rest 41 eyes were clear. One eye underwent re-treatment due to myopic regression 15 months after initial treatment.

Conclusions:

Flap Off Epi-Lasik appeared to be effective and safe in the treatment of high myopia and myopic astigmatism (≥8,00 sph.eq).

Financial Disclosure:

No

Back to previous